Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 23543091)

1.

The μ-opioid receptor and treatment response to naltrexone.

Thorsell A.

Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. doi: 10.1093/alcalc/agt030. Epub 2013 Mar 29. Review.

2.
3.

The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.

Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF.

Alcohol Clin Exp Res. 2012 Mar;36(3):385-94. doi: 10.1111/j.1530-0277.2011.01633.x. Epub 2011 Sep 6. Review.

4.

Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.

Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, Henderson S, Myrick H.

Neuropsychopharmacology. 2013 Feb;38(3):414-22. doi: 10.1038/npp.2012.195. Epub 2012 Oct 3.

5.

Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.

Ray LA, Bujarski S, Chin PF, Miotto K.

Neuropsychopharmacology. 2012 Jan;37(2):445-55. doi: 10.1038/npp.2011.192. Epub 2011 Sep 7.

6.

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.

Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R, Sullivan T, Somogyi AA, White JM.

Pharmacogenet Genomics. 2011 Dec;21(12):902-5. doi: 10.1097/FPC.0b013e32834c5445.

PMID:
21946895
7.

Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.

Anton RF, Voronin KK, Randall PK, Myrick H, Tiffany A.

Alcohol Clin Exp Res. 2012 Nov;36(11):2000-7. doi: 10.1111/j.1530-0277.2012.01807.x. Epub 2012 May 2.

8.

Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.

Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH; VA Cooperative Study #425 Study Group.

Alcohol Clin Exp Res. 2007 Apr;31(4):555-63.

PMID:
17374034
9.

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.

Setiawan E, Pihl RO, Benkelfat C, Leyton M.

Pharmacogenomics. 2012 Jul;13(10):1161-72. doi: 10.2217/pgs.12.99. Review.

PMID:
22909206
10.

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.

Chamorro AJ, Marcos M, Mirón-Canelo JA, Pastor I, González-Sarmiento R, Laso FJ.

Addict Biol. 2012 May;17(3):505-12. doi: 10.1111/j.1369-1600.2012.00442.x. Review.

PMID:
22515274
11.

[Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].

Kato H.

Nihon Arukoru Yakubutsu Igakkai Zasshi. 2008 Oct;43(5):697-704. Review. Japanese.

PMID:
19068776
12.

Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.

Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ, Heilig M.

Biol Psychiatry. 2010 Jan 1;67(1):78-80. doi: 10.1016/j.biopsych.2009.07.026. Epub .

13.

Pharmacogenetic treatments for drug addiction: alcohol and opiates.

Haile CN, Kosten TA, Kosten TR.

Am J Drug Alcohol Abuse. 2008;34(4):355-81. doi: 10.1080/00952990802122564. Review.

PMID:
18584566
14.

Opioid pharmacogenetics of alcohol addiction.

Berrettini W.

Cold Spring Harb Perspect Med. 2013 Jul 1;3(7). pii: a012203. doi: 10.1101/cshperspect.a012203. Review.

PMID:
23729643
15.

A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.

Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW.

Psychopharmacology (Berl). 2009 Jan;201(4):611-8. doi: 10.1007/s00213-008-1330-5. Epub 2008 Sep 16.

PMID:
18795264
16.
17.

A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.

Vallender EJ, Rüedi-Bettschen D, Miller GM, Platt DM.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):252-6. doi: 10.1016/j.drugalcdep.2010.01.005. Epub 2010 Feb 13.

18.

Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.

Kranzler HR, Armeli S, Covault J, Tennen H.

Addict Biol. 2013 Jan;18(1):193-201. doi: 10.1111/j.1369-1600.2012.00471.x. Epub 2012 Jul 11.

19.

OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.

Oroszi G, Anton RF, O'Malley S, Swift R, Pettinati H, Couper D, Yuan Q, Goldman D.

Alcohol Clin Exp Res. 2009 Mar;33(3):383-93. doi: 10.1111/j.1530-0277.2008.00846.x. Epub 2008 Nov 25.

20.

COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.

Goldman D, Oroszi G, O'Malley S, Anton R.

J Stud Alcohol Suppl. 2005 Jul;(15):56-64; discussion 33. Review.

PMID:
16223057
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk